2024
Glial modulators as novel therapeutics for comorbid pain and opioid use disorder
Schwartz E, De Aquino J, Sofuoglu M. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 3054-3066. PMID: 38752593, DOI: 10.1111/bcp.16094.Peer-Reviewed Original ResearchOpioid use disorderChronic painGlial modulationNovel treatment approachesComorbid painPublic health problemTreatment approachesImproved pain measuresLiterature search of PubMedIncreased opioid prescriptionsSearch of PubMedAddiction-related outcomesSignificant public health problemComorbid disordersOpioid prescriptionsGoogle Scholar databasesPain measuresHealth problemsPain managementClinical studiesTreatment challengesClinical trialsPatient populationPainGlial activationFrom taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff J, Nunes J, Costa G, Sofuoglu M, MacLean R, De Aquino J. From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 3036-3053. PMID: 38627909, PMCID: PMC11480258, DOI: 10.1111/bcp.16045.Peer-Reviewed Original ResearchOpioid use disorderChronic painLong-term opioid therapyManagement of chronic painPain management alternativeOpioid-induced analgesiaInnovative treatment optionsManagement of painReverse painCentral sensitizationOpioid therapyPain controlTreatment optionsClinical challengeClinical trialsPainPotential therapeutic applicationsPain experiencePotential of psychedelicsNovel therapeuticsHuman evidenceOpioid crisisNeurobiological substratesOpioidExploration of novel therapeuticsEfficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment
MacLean R, Ankawi B, Driscoll M, Gordon M, Frankforter T, Nich C, Szollosy S, Loya J, Brito L, Ribeiro M, Edmond S, Becker W, Martino S, Sofuoglu M, Heapy A. Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment. JMIR Research Protocols 2024, 13: e54342. PMID: 38506917, PMCID: PMC10993119, DOI: 10.2196/54342.Peer-Reviewed Original Research
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liability
2021
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trials
2019
Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Stimulants and Mood Disorders
MacLean R, Sofuoglu M. Stimulants and Mood Disorders. Current Addiction Reports 2018, 5: 323-329. DOI: 10.1007/s40429-018-0212-0.Peer-Reviewed Original ResearchStimulant use disorderMood disordersUse disordersSUD comorbidityClinical trialsComorbid substance use disorderRecent FindingsEpidemiological studiesCo-occurring mood disordersSubstance use disordersMethamphetamine use disorderMajority of trialsClinical outcomesPharmacological treatmentTreatment responseNeurobiological mechanismsDisordersMultiple studiesTrialsComorbiditiesPatientsDiagnosisMoodTreatmentPurposeToEpidemiology
2015
COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBT
Carroll K, Herman A, DeVito E, Frankforter T, Sofuoglu M. COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBT. Drug And Alcohol Dependence 2015, 146: e240. DOI: 10.1016/j.drugalcdep.2014.09.120.Peer-Reviewed Original Research